About the Myelodysplastic Syndromes Session
Myelodysplastic syndromes (MDS) constitute a group of blood disorders characterized by dysfunctional bone marrow, leading to ineffective blood cell production. While not always cancerous, MDS can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer. Cancer research in MDS focuses on understanding the molecular mechanisms driving disease progression and identifying novel therapeutic targets. Recent advancements include the development of targeted therapies aimed at restoring normal blood cell production and improving patient outcomes. Additionally, studies exploring the role of immunotherapy and epigenetic modifiers in MDS management offer promising avenues for future treatment strategies. Continued research efforts are essential to unravel the complexities of MDS and devise more effective therapies for patients afflicted with this challenging condition.
Topics Covered in Myelodysplastic Syndromes
Clonal Hematopoiesis
Prognostic Risk Scoring
Anemia Management
Hypomethylating Agents
Stem Cell Transplant
Leukemic Progression
Related Scientific Sessions at CIOC 2027
Why Attend the Myelodysplastic Syndromes Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Myelodysplastic Syndromes work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Myelodysplastic Syndromes research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Myelodysplastic Syndromes track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Myelodysplastic Syndromes Conference 2027 — FAQs
What is the Myelodysplastic Syndromes track at CIOC 2027?
The Myelodysplastic Syndromes track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Myelodysplastic Syndromes. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Myelodysplastic Syndromes sessions?
Cancer researchers and clinicians, educators and students with an interest in Myelodysplastic Syndromes are all welcome — whether presenting or attending.
Can I present my research in the Myelodysplastic Syndromes track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Myelodysplastic Syndromes sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Myelodysplastic Syndromes track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.